Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 24 articles:
HTML format



Single Articles


    November 2022

  1. Correction to: RE: Grade Migration of Prostate Cancer in the United States During the Last Decade.
    J Natl Cancer Inst. 2022 Nov 15. pii: 6827851. doi: 10.1093.
    PubMed    


    October 2022
  2. PAGADALA MS, Lynch J, Karunamuni R, Alba PR, et al
    Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.
    J Natl Cancer Inst. 2022 Oct 28. pii: 6777270. doi: 10.1093.
    PubMed     Abstract available


  3. SHIH YT, Xu Y, Bradley C, Giordano SH, et al
    Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured.
    J Natl Cancer Inst. 2022;114:1392-1399.
    PubMed     Abstract available


    September 2022
  4. AWASTHI S, Grass GD, Torres-Roca J, Johnstone PAS, et al
    Genomic testing in localized prostate cancer can identify subsets of African-Americans with aggressive disease.
    J Natl Cancer Inst. 2022 Sep 2. pii: 6687132. doi: 10.1093.
    PubMed     Abstract available


    July 2022
  5. TAKAHASHI T
    RE: Grade Migration of Prostate Cancer in the United States during the last decade.
    J Natl Cancer Inst. 2022 Jul 26. pii: 6650145. doi: 10.1093.
    PubMed    


    June 2022
  6. KEATING NL, Brooks GA, Landrum MB, Liu PH, et al
    The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
    J Natl Cancer Inst. 2022;114:871-877.
    PubMed     Abstract available


    April 2022
  7. LAI LY, Oerline MK, Caram MEV, Tsao PA, et al
    Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer.
    J Natl Cancer Inst. 2022 Apr 13. pii: 6568024. doi: 10.1093.
    PubMed     Abstract available


  8. KEATING NL
    Cardiovascular and Metabolic Diagnoses Associated with Novel Hormonal Agents for Prostate Cancer in Non-Trial Populations.
    J Natl Cancer Inst. 2022 Apr 13. pii: 6568021. doi: 10.1093.
    PubMed    


  9. QIAO EM, Lynch JA, Lee KM, Kotha NV, et al
    Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer.
    J Natl Cancer Inst. 2022;114:592-599.
    PubMed     Abstract available


    March 2022
  10. BORREGALES LD, DeMeo G, Gu X, Cheng E, et al
    Grade Migration of Prostate Cancer in the United States during the last decade.
    J Natl Cancer Inst. 2022 Mar 28. pii: 6555003. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  11. MARK M, von Moos R, Cathomas R, Stoffel S, et al
    RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    J Natl Cancer Inst. 2021 Nov 29. pii: 6446038. doi: 10.1093.
    PubMed    


    October 2021
  12. MITCHELL AP, Mishra A, Panageas KS, Lipitz-Snyderman A, et al
    Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    J Natl Cancer Inst. 2021 Oct 1. pii: 6379715. doi: 10.1093.
    PubMed     Abstract available


    July 2021
  13. BARNES DR, Silvestri V, Leslie G, McGuffog L, et al
    Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329642. doi: 10.1093.
    PubMed     Abstract available


  14. HAWLEY JE, Pan S, Kandadi H, Chaimowitz MG, et al
    Analysis of Circulating Immune Biomarkers by Race in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Sipuleucel-T.
    J Natl Cancer Inst. 2021 Jul 24. pii: 6327691. doi: 10.1093.
    PubMed     Abstract available


  15. KIELY M, Milne GL, Minas TZ, Dorsey TH, et al
    Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men.
    J Natl Cancer Inst. 2021 Jul 15. pii: 6321959. doi: 10.1093.
    PubMed     Abstract available


    May 2021
  16. BRAWLEY OW, Paller CJ
    The Realities of Prostate Cancer Screening, Treatment, and Race.
    J Natl Cancer Inst. 2021 May 8. pii: 6272521. doi: 10.1093.
    PubMed    


  17. NYAME YA, Gulati R, Heijnsdijk EAM, Tsodikov A, et al
    The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis.
    J Natl Cancer Inst. 2021 May 8. pii: 6272520. doi: 10.1093.
    PubMed     Abstract available


  18. OLSSON H, Nordstrom T, Jaderling F, Egevad L, et al
    Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS).
    J Natl Cancer Inst. 2021;113:632-640.
    PubMed     Abstract available


  19. BECKER DJ, Rude T, Walter D, Wang C, et al
    The Association of Veterans' PSA Screening Rates With Changes in USPSTF Recommendations.
    J Natl Cancer Inst. 2021;113:626-631.
    PubMed     Abstract available


    April 2021
  20. KLEBANER D, Travis Courtney P, Garraway IP, Einck J, et al
    Association of Health-Care System with Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men.
    J Natl Cancer Inst. 2021 Apr 21. pii: 6248098. doi: 10.1093.
    PubMed     Abstract available


  21. WANG L, Paller C, Hong H, Rosman L, et al
    Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.
    J Natl Cancer Inst. 2021 Apr 8. pii: 6217361. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  22. HEWITT SM
    The Challenges of Optimizing Biomarkers to Guide Clinical Decision Making.
    J Natl Cancer Inst. 2020;112:1079-1080.
    PubMed    


    October 2020
  23. FEDEWA SA, Ma J, Jemal A
    Response to Lehrer and Rheinstein.
    J Natl Cancer Inst. 2020;112:1069-1070.
    PubMed    


    September 2020
  24. BROWN DW, Machiela MJ
    Why Y? Downregulation of Chromosome Y Genes Potentially Contributes to Elevated Cancer Risk.
    J Natl Cancer Inst. 2020;112:871-872.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: